首页> 外国专利> AGENT FOR PREVENTING AND TREATING INTRAHEPATIC STONE, OR AGENT FOR PREVENTING RELAPSE THEREOF

AGENT FOR PREVENTING AND TREATING INTRAHEPATIC STONE, OR AGENT FOR PREVENTING RELAPSE THEREOF

机译:预防和治疗肝内结石的代理商,或预防肝内粘连的代理商

摘要

PROBLEM TO BE SOLVED: To provide an agent for preventing and treating intrahepatic stone, having excellent effects of enhancing the expression of human MDR3 on the pleural membrane of the bile duct, and accelerating the transportation of phospholipids to the bile duct, and to provide an agent for preventing the relapse thereof.;SOLUTION: The medicinal composition contains α-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid (general name: bezafibrate) represented by the formula, or a pharmacologically acceptable salt thereof as an active ingredient. For example, when the bezafibrate of an active ingredient is orally administered, the dose per adult per day is 100-1,000 mg, preferably 400-600 mg, and the dose may be increased or decreased according to the symptom.;COPYRIGHT: (C)2004,JPO
机译:要解决的问题:提供一种预防和治疗肝内结石的药物,该药物具有增强人类MDR3在胆管胸膜上的表达并促进磷脂向胆管运输的优异效果,并提供解决方案:药物组合物包含由式表示的α-[4-(4-氯苯甲酰氨基乙基)苯氧基]异丁酸(通称:苯扎贝特)或其药理学上可接受的盐作为有效成分。 。例如,当口服给予活性成分苯扎贝特时,每位成人每天的剂量为100-1,000 mg,优选为400-600 mg,并且剂量可以根据症状增加或减少。 2004年,日本特许厅

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号